Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Prices IPO at $9 per Share

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics today priced its initial public offering at $9 per share, below the $12 to $14 range the company had earlier projected.

The shares are expected to begin trading on the Nasdaq Global Market today under ticker symbol "GNOM."

The Mountain View, Calif.-based sequencing services firm is selling 6 million shares in the offering. The total proceeds to be raised — $54 million — falls short of the $96.6 million that Complete Genomics had most recently targeted and is below the $86.3 million it had targeted when it filed its IPO in July.

In a document filed with the US Securities and Exchange Commission yesterday, the company said it expects to receive net proceeds of $47 million from today's offering. If its underwriters exercise over-allotment options in full, net proceeds will total $54.5 million.

UBS Investment Bank and Jefferies & Company are joint book-running managers for the offering. Baird and Cowen and Company are co-managers.

The firm said that about $20 million from the net proceeds will go toward capital expenditures to expand the firm's sequencing and computing capacity at its facility in Mountain View. Another $15 million is expected to be used to further develop of its sequencing technology and services, it said.

Complete Genomics' IPO follows Pacific Biosciences' IPO two weeks ago, which raised $200 million.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.